Editorial Article:

Harnessing the Power of the Immune System: Optimizing T Cell Killing Cancer Immunotherapy

Novel T cell-based immune therapies, including chimeric antigen receptor T cell (CAR-T) therapy and TCR-based adoptive T cell (TCR-T) therapy, has emerged as a real game-changer in cancer therapeutics. These new approaches are particularly beneficial for those with malignancies previously considered ‘difficult to treat’.

Read the interview by Dr. Amir Alpert, senior scientist at Immatics US Inc., titled “Harnessing the Power of the Immune System: Optimizing T Cell Killing Cancer Immunotherapy” in which Dr. Alpert describes his efforts and approach to developing multiple TCR-based adoptive T cell therapies targeting cancer, the advantages of TCR-T therapy over other immunotherapies such as CAR-T, and how the IncuCyte® Live-Cell Analysis System has been integral in advancing this research.

Complete the form below to download the white paper.

Harnessing-the-Power-of-the-Immune-System-pg1


No file selected
0%
Stay up-to-date with what's happening at Essen BioScience

© 2019 Essen BioScience

Privacy Policy